Amgen KIF18A Kinase Inhibitor Patent Application for Cancer Treatment
Summary
USPTO published Amgen's patent application US20260098029A1 for KIF18A protein-modulating compounds intended to treat cancer and cancer-related diseases. The application discloses compounds of formula (I) with synthetic intermediates, pharmaceutical compositions, and methods of treatment. The 15 named inventors include researchers from Amgen's medicinal chemistry and oncology teams.
What changed
USPTO published Amgen's patent application disclosing novel KIF18A kinase inhibitor compounds for cancer treatment. The application covers compounds capable of modulating KIF18A protein to influence cell cycle and cell proliferation, pharmaceutical compositions containing these compounds, and methods of treating KIF18A-related diseases including various cancers.
For pharmaceutical manufacturers and biotech companies developing oncology therapeutics, this patent represents potential freedom-to-operate considerations. Competitors in the KIF18A inhibitor space should evaluate the claimed compound structures and treatment methods to assess potential infringement risks or identify distinct design-around opportunities.
What to do next
- Monitor patent prosecution status for scope amendments
- Review Freedom to Operate if developing competing KIF18A inhibitors
- Assess patent landscape for licensing opportunities
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
KIF18A INHIBITORS
Application US20260098029A1 Kind: A1 Apr 09, 2026
Assignee
AMGEN INC.
Inventors
Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J. FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA
Abstract
Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
CPC Classifications
C07D 401/14 C07D 401/12 C07D 405/14 C07D 413/14 C07D 419/14 C07D 491/107
Filing Date
2025-10-15
Application No.
19359179
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.